“Serious adverse reactions could occur in patients with a sulfite allergy who are exposed to hydromorphone containing sulfites,” the company said in its recall notice.
The affected product is 0.5 mg/mL hydromorphone HCl in 0.9 percent sodium chloride 1 mL in 3 mL BD syringe.
PharMEDium said it has notified its customers and arranged replacement orders.
More articles on pharmacy:
Walmart cutting some pharmacy jobs
UPMC acquires community pharmacy in Pittsburgh
Oklahoma judge approves Teva’s $85M opioid settlement
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.